Background
==========

Brain Cell Membrane Protein 1 (BCMP1) cDNA was fortuitously isolated from a thyroid cDNA library \[[@B1]\]. It encodes a 181aa-long putative four-transmembrane domain protein which appears related to both Peripheral Myelin Protein 22 / Epithelial Membrane Proteins and Claudins protein families, and exhibits significant similarities to the *Caenorhabditis elegans*VAB-9 protein, a protein that has recently been shown to be involved in the control of cell adhesion and epidermal morphology \[[@B2]\]. The protein sequence itself has been extremely well conserved during evolution, as exemplified by the observation that human and canine sequences are identical and differ from the mouse sequence at only 2 positions. The corresponding gene has now been renamed TM4SF10 in man and mouse, and is located on the X chromosome in both species, as well as in the other mammalian species investigated to date \[[@B1]\].

Initial Northern blot analysis of TM4SF10/BCMP1 gene transcripts distribution in adult dog tissues revealed very high expression in the brain, and lower but clearly detectable levels of expression in most of the tissues examined \[[@B1]\]. Data mining in the SAGEmap database \[[@B3]\] confirmed this observation in man, as elevated tag counts have been reported in brain astrocytoma (SAGE H127 library), brain ependymoma (SAGE ependymoma 353 and 582 libraries) and normal spinal cord (SAGE normal spinal cord library) as compared to other tissues. Together with its localization on the X chromosome, the high expression level detected in the brain and the putative role of the encoded protein in specific cell contacts raised the possibility that the TM4SF10 gene may be involved in X-linked mental retardation (XLMR) in man.

Initially, the TM4SF10 gene was assigned to Xp11.4 \[[@B1]\]. As the integration between human cytogenetic and DNA sequence-based maps is still evolving, the gene has been reassigned to band p21.1. It is noteworthy that TM4SF2, another gene encoding a four-transmembrane domain protein, is located at the p11.4-p21.1 border on human chromosome X, in the very close vicinity of TM4SF10, and constitutes a known XLMR gene \[[@B4],[@B5]\]. Recent compilations of XLMR families \[[@B6]-[@B8]\] mention several conditions mapped to the Xp11.4-p21.1 region. We report the result of mutation screening of TM4SF10 in a cohort of XLMR patients whose gene was mapped to this region of the X chromosome and does not correspond to TM4SF2.

Methods
=======

Blood genomic DNA was collected from 16 patients (14 unrelated) and 5 unrelated healthy volunteers using a standard procedure \[[@B9]\]. The patients were affected males from families with definite, or possible, linkage to the region at Xp11.4-p21.1. Patients belonged to the following published MRX(S) families: MRX9 \[[@B10]\], MRX10 \[[@B11]\], MRX11 \[[@B11]\], MRX12 \[[@B11]\], MRX18 \[[@B12]\], MRX56 \[[@B6]\] and MRXS10 \[[@B13]\]. Additional patients were from an XLMR family with epilepsy \[[@B14]\] and 4 other XLMR families (C.S., F.K., J.G., unpublished), a MRXS family with macrocephaly and large ears (C.S., unpublished), and another MRXS family (J.G., unpublished). Chromosomal linkage data and major phenotypic traits are described in table [1](#T1){ref-type="table"}. All samples were studied anonymously and all procedures met the standards of our institutional ethics committee.

###### 

Description of the patients included in the study

  Patient   Family                                 Linkage data                    Phenotype
  --------- -------------------------------------- ------------------------------- ----------------------------------------------------------------------------------------------------------
  P1, P2    XLMR family (F.K., now MRX79)          chromosome X                    X-linked mental retardation
  P3, P4    MRXS10                                 Xp11.21-Xp11.4                  Mental retardation, choreoathetosis, abnormal behavior
  P5        XLMR family (F.K.)                     Chromosome X, pericentromeric   Non-syndromic mental retardation
  P6        MRX9                                   Xp11.22-Xp11.4                  Non-syndromic mental retardation
  P7        MRX10                                  Xp11.3-Xp21.2                   Non-syndromic mental retardation
  P8        MRX11                                  Xp11.3-Xp21.2                   Non-syndromic mental retardation
  P9        MRX12                                  Xp11.21-Xp21.2                  Non-syndromic mental retardation
  P10       MRX18                                  Xp11.3-Xp21.2                   Non-syndromic mental retardation
  P11       XLMR family with epilepsy              Xp11.23-Xp22.22                 Non-syndromic mental retardation, epilepsy
  P12       MRXS family (J.G.)                     Xp21.3-Xq21.3                   Non-syndromic mental retardation
  P13       XLMR family with macrocephaly (J.G.)   Xp11.4-Xq13.1                   Macrocephaly, moderate to profound mental retardation
  P14       XLMR family (C.S.)                     Xp11.3-Xp21.1                   Seizures, ataxia, aggressive and hyperactive behavior, speech delay, mild to moderate mental retardation
  P15       MRXS (C.S.)                            Xp22.22-Xq24                    Macrocephaly, prominent ears and moderate to severe mental retardation
  P16       MRX56                                  Xp11.21-Xp21.1                  Non-syndromic mental retardation

PCR reactions were performed in a final volume of 100 μl containing 200 ng of genomic DNA, 1 μg of each primer (see table [2](#T2){ref-type="table"} for primer sequences), 200 μM of each dNTP, 1X PCR buffer (QIAGEN) and 2.5 units of Taq polymerase (QIAGEN). Additionally, 10% DMSO or 20% Q solution (QIAGEN) were also included in some reactions (see table [2](#T2){ref-type="table"}). After an initial denaturation step (93°C, 45 sec.), 35 cycles were conducted as follows: 93°C, 45 sec.; annealing temp. (see table [2](#T2){ref-type="table"}), 45 sec.; 72°C, 45 sec. (amplicons Ex1--Ex3) or 1 min. (amplicons 3\'UTR F1--F4). A final extension step (72°C, 3 min.) was done at the end of the reaction. PCR products were purified using the QIAquick PCR purification kit (QIAGEN) before sequencing. Purified PCR fragments were roughly quantitated by agarose gel electrophoresis using SmartLadder molecular weight marker (EUROGENTEC) as a quantitative reference.

###### 

PCR conditions and primer sequences used to amplify TM4SF10 gene fragments from total genomic DNA

  Amplicon    Size      Primer sequence                                               PCR conditions
  ----------- --------- ------------------------------------------------------------- ---------------------------------
  Ex1         442 bp    fw: AGAGCCCCGAGGGAGCGA, rev: GGGGACAGGCGGTGACTG               T~anneal~= 55°C, 10% DMSO
  Ex2         447 bp    fw: AAATCCTAGCAAACCCCTGG, rev: TCTGCATAGGAAAGGAAGATGG         T~anneal~= 50°C
  Ex3         447 bp    fw: CCATCTAGAACAAGCCATCTTTAA, rev: TAAATCAACTGAGCAAACTGCTTG   T~anneal~= 50°C
  3\'UTR F1   959 bp    fw: GGCCTGGGGTGCAACTATAT, rev: TAGGCAAATGTATGTGGAGGGT         T~anneal~= 55°C, 10% DMSO
  3\'UTR F2   1101 bp   fw: ATTGGTGCCTCAGCCCTATCTA, rev: GCAACCATTCTTAAGACAAGCT       T~anneal~= 57°C, 20% Q solution
  3\'UTR F3   1130 bp   fw : CAGTATGTTCTGGTTTTGGCCC, rev : TATCTAACAATGGGTTTGTGGC     T~anneal~= 57°C, 20% Q solution
  3\'UTR F4   1097 bp   fw : CCTTCTCAGCAAAGAGCCCTAC, rev : AAGGATCTTGGGAGATAATTTG     T~anneal~= 57°C, 20% Q solution

About 50--100 ng of purified PCR fragment was used in a DNA sequencing reaction using a nested, internal primer. DNA sequencing was performed using ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on an Applied Biosystems 3100 automatic DNA sequencer. The sequences of the primers are given in table [3](#T3){ref-type="table"}.

###### 

Sequences of the primers used for sequencing of TM4SF10 gene fragments

  Amplicon    Primer sequence
  ----------- ------------------------------------------------------------------------------------------
  Ex1         fw: CCGAGGGAGCGAGTCCCC
  Ex2         fw: CACATCTGTTGAGCCACTGC
  Ex3         rev: GATGCTCCACAAGTGTTTTAGA
  3\'UTR F1   fw : TGCCTGAACCCTAAGAACTATG, rev : GGAGGGTTAGGGAACAACTTAT
  3\'UTR F2   fw : CTGCATGAGTTGCTTTTGTACC, rev : GCAACCATTCTTAAGACAAGCT
  3\'UTR F3   fw : TCTGTTAAGAGCAGGACCACAT, rev1: ACTCGAGATGTGATGATATTGG, rev2 : TATCTAACAATGGGTTTGTGGC
  3\'UTR F4   fw : AACATGAAAATTGTTGCTTCTC, rev : AAGGATCTTGGGAGATAATTTG

Results and discussion
======================

Sequencing of TM4SF10 coding region
-----------------------------------

The human TM4SF10 gene is composed of 3 exons and produces a 4 kb-long mRNA. The short coding region (543 bp) is interrupted by 2 introns and the last and the largest exon also contains a 3 233 bp-long 3\'UTR (see Figure [1](#F1){ref-type="fig"}). Initially, we sequenced the coding region and exon-intron junctions of the gene in the DNAs from 16 XLMR patients and from one normal male (amplicons Ex1--Ex3, Figure [1](#F1){ref-type="fig"}). No mutations were identified. One silent polymorphism was observed at position 186 in the cDNA sequence (clone DKFZp761J17121; GenBank accession number AL136550), corresponding to the 3^rd^base of the codon Arg59, where a C residue was present in half of the sequences and a G residue in the other half. Individual single nucleotide polymorphism (SNP) data are shown in table [4](#T4){ref-type="table"}. It is noteworthy that patients P3 and P4 who belong to the same family exhibit a difference in their TM4SF10 gene sequence at this level. This observation argues against a causal role of the gene in this family. The 186C\>G polymorphism in the TM4SF10 gene had been previously reported \[[@B15]\].

![**Schematic of the TM4SF10 gene and single nucleotide polymorphisms identified in the study.**The structure of the gene is outlined with exons represented as light-blue boxes and the coding region as dark-blue areas within the boxes. The 3\' end of the gene is also enlarged (bottom). Amplified regions are delineated and locations of sequence primers (arrows) used in this study are depicted. Identified SNPs are indicated (dotted lines) with reference to genomic contig (GenBank accession number NT_011757) sequence coordinates and cDNA (clone DKFZp761J17121; GenBank accession numberAL136550) sequence coordinates (italics) when relevant. Numbers in parentheses indicate the occurrences of the nucleotide in the individual sequences. The 3 novel SNPs identified in the work appear in red.](1471-2350-5-22-1){#F1}

###### 

Description of the individual TM4SF10 gene SNP haplotypes determined in this study

        Exon 1: 186 (Arg59), \[21589434\]   3\' UTR: 705, \[21562747\]   3\' UTR: 2870, \[21560583\]   3\' UTR: 2907, \[21560546\]   3\' intergenic: \[21559611\]
  ----- ----------------------------------- ---------------------------- ----------------------------- ----------------------------- ------------------------------
  N1    C                                   C                            G                             T                             C
  N2    (n.d.)                              C                            C                             C                             C
  N3    (n.d.)                              C                            C                             T                             C
  N4    (n.d.)                              T                            C                             T                             T
  N5    (n.d.)                              C                            C                             T                             C
  P1    C                                   T                            C                             T                             T
  P2    C                                   T                            C                             T                             T
  P3    G                                   C                            C                             T                             C
  P4    C                                   C                            C                             T                             C
  P5    G                                   C                            C                             T                             T
  P6    G                                   C                            C                             T                             T
  P7    G                                   C                            C                             T                             C
  P8    G                                   C                            C                             T                             C
  P9    G                                   C                            C                             T                             C
  P10   C                                   C                            C                             T                             T
  P11   C                                   T                            C                             T                             T
  P12   G                                   C                            C                             T                             C
  P13   G                                   C                            C                             T                             C
  P14   C                                   C                            C                             T                             T
  P15   C                                   T                            C                             T                             T
  P16   G                                   C                            C                             T                             C

The first row identifies the source of the DNA, either a normal individual (Nx) or a patient (Px; see also table 1 for the detailed description of the patients). The individual bases found at each polymorphic position in the DNA sequence (identified by the nucleotide position in the cDNA sequence and/or in the genomic contig sequence \[in square brackets\]; see also figure 1) are given in the following rows. (n.d.): not determined.

Sequencing of the 3\'UTR
------------------------

The long 3\'UTR sequence of the TM4SF10/BCMP1 transcript is highly conserved, with an overall score of 72% when human, dog, mouse and rat sequences are compared. As the 3\'UTR of mRNAs may contain regulatory sequences that participate in the control of gene expression, we decided to screen this part of the gene as well. The entire region, including the sequences around the polyadenylation site, was subdivided into four overlapping fragments of approximately 1 kb in length (3\'UTR F1--F4, Figure [1](#F1){ref-type="fig"}) and sequenced from both ends. In fragment 3\' UTR F3 the presence of a stretch of 12 consecutive A residues on the sense strand resulted in difficulties in proper reading of the sequences located downstream of this motif. In order to overcome this problem, an additional sequence primer (rev2) was used to obtain overlaps between the 3 separate sequences for each individual fragment. In the cDNA sequence AL136550 the motif is composed of 13 A residues, which is a likely sequence artefact.

TM4SF10 sequence was obtained from 16 patients and 5 controls. Four SNPs were identified in the non-coding part of the gene: 3 of them were located in the 3\'UTR of the mRNA while the fourth one was located downstream of the polyadenylation site (Figure [1](#F1){ref-type="fig"}). Only this last one (C21559611T) had been previously reported in the SNP database \[[@B15]\], the other three representing novel SNPs in the TM4SF10 gene. The individual SNP haplotypes determined here are described in table [4](#T4){ref-type="table"}. It is also noteworthy that during the course of our investigation, the genetic defect of one of the unpublished XLMR family included in the study (see top of table [1](#T1){ref-type="table"}) has been identified and mapped to Xq28, within the MECP2 gene \[[@B16]\].

Conclusions
===========

In this study, we have investigated the majority of the known MRX families linked to the TM4SF10 gene region. In the absence of mutations detected, our results indicate that alterations in the transcribed region of TM4SF10 are not a frequent cause of XLMR. Although the gene promoter has not been identified and screened yet, it appears very unlikely that all mutations would be there.

This work also identified three novel SNPs in the TM4SF10 gene, which adds to our knowledge of SNP occurrence within this gene.
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